Pilot Study: Ultrasonic Debris Clearance for Alzheimer's Risk

This study is testing a new device called Ultrasonic Debris Clearance (UDC) to see if it's safe and works well for people at risk of Alzheimer's disease. UDC uses low-intensity ultrasound to help clear out harmful substances in the brain. You might be able to join if you are 18 or older and have signs of amyloid (a protein linked to Alzheimer's) in your brain, even if you don't have symptoms yet, or if you have mild memory problems. The study will compare UDC to a sham procedure (a fake treatment) to see if UDC can be given safely and if it shows any early signs of helping. We are looking for 15 participants.

Study design
This is an interventional study with 15 planned participants. It compares Ultrasonic Debris Clearance (UDC) to a sham procedure, where participants are blinded to which treatment they receive.
What's involved
You would receive 8 sessions of either UDC or a sham procedure over 4 weeks, with each session lasting about 30 minutes. Your safety will be monitored from the start of treatment up to 3 months later.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored from the start of treatment through 2 months post-treatment initiation, which is up to 3 months in total.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07573982

Ultrasonic Debris Clearance to Promote Brain Resilience

Not Yet Recruiting
NAAges 18+Interventional
Stanford University
~15 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:Ultrasonic Debris Clearancesham

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Treatment-Related Adverse Events
Measured over baseline through 2 months post-treatment initiation (up to 3 months)
Alzheimer s Disease
MCI With Increased Risk for Alzheimer Disease
1 sites across 1 states
California1
  • Raag Airan, MD, PhD · PRINCIPAL_INVESTIGATOR · Stanford University

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Number of Participants with Treatment-Related Adverse Eventsbaseline through 2 months post-treatment initiation (up to 3 months)

    All reported adverse events including clinically meaningful vital sign changes, laboratory test abnormalities, physical and cognitive symptoms, and new imaging abnormalities not present at baseline.